Dated: June 5, 1997.

Richard Sorian,

Deputy Director, Advisory Commission on Consumer Protection and Quality in the Health Care Industry.

[FR Doc. 97–15391 Filed 6–11–97; 8:45 am]

BILLING CODE 4110–60–M

DEPARTMENT OF THE INTERIOR

[MT–960–1150–00]

District Advisory Council Meeting

AGENCY: Bureau of Land Management, Dakotas District Office, Interior.

ACTION: Notice of meeting.

SUMMARY: A meeting of the Dakotas District Resource Advisory Council will be held July 31–August 1, 1997, at the C & L Cafe, 21 North Main Street, Bowman, North Dakota. The sessions will convene at 8:00 a.m. on both days. Agenda items include updates on the North Dakota Mineral Exchange, South Dakota Land Exchange, and field examination of rangeland and mineral activities.

The meeting is open to the public and a public comment period is set for 8:00 a.m. on August 1st. The public may make oral statements before the Council or file written statements for the Council to consider. Depending on the number of persons wishing to make an oral statement, a per-person time limit may be established. Summary minutes of the meeting will be available for public inspection and copying during regular business hours.

The 12-member Council advises the Secretary of the Interior, through the BLM, on a variety of planning and management issues associated with public land management in the Dakotas.

FOR FURTHER INFORMATION CONTACT: Jon Pinner, Administrative Officer, Dakotas District Office, 2933 3rd Avenue West, Dickinson, ND 58601. Telephone (701) 225–9148.

Dated: June 2, 1997.

Douglas J. Burger,

District Manager.

[FR Doc. 97–15401 Filed 6–11–97; 8:45 am]

BILLING CODE 4310–DN–P

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation

Meeting of the Conservation Advisory Group, Yakima River Basin Water Enhancement Project, Yakima, Washington

AGENCY: Department of the Interior.

ACTION: Notice of meeting.

SUMMARY: As required by the Federal Advisory Committee Act, notice is hereby given that the Conservation Advisory Group, Yakima River Basin Water Enhancement Project, Yakima, Washington, established by the Secretary of the Interior, will hold a public meeting. The purpose of the Conservation Advisory Group is to provide technical advice and counsel to the Secretary and the State on the structure, implementation, and oversight of the Yakima River Basin Water Conservation Program.

DATES: Wednesday, June 25, 1997, 9 a.m.–4 p.m.

ADDRESSES: Bureau of Reclamation Office, 1917 Marsh Road, Yakima, Washington.

FOR FURTHER INFORMATION CONTACT: Dave Kaumheimer, Acting Program Manager, Yakima River Water Enhancement Project, P.O. Box 1749, Yakima, Washington, 98907; (509) 575–5848, extension 232.

SUPPLEMENTARY INFORMATION: The Basin Conservation Program is structured to provide economic incentives with cooperative Federal, State, and local funding to stimulate the identification and implementation of structural and nonstructural cost-effective water conservation measures in the Yakima River basin. Improvements in the efficiency of water delivery and use will result in improved stream flows for fish and wildlife and improve the reliability of water supplies for irrigation.

Dated: June 4, 1997.

Hollis Pope,

Acting Area Manager, Upper Columbia Area.

[FR Doc. 97–15418 Filed 6–11–97; 8:45 am]

BILLING CODE 4310–94–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Chandra M. Katta, M.D.; Revocation of Registration

On January 29, 1997, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), issued an Order to show Cause to Chandra M. Katta, M.D., of Morgan City, Louisiana, notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificates of Registration, AK3284647 and BK2580769, under 21 U.S.C. 824(a)(3), and deny any pending applications for renewal of such registrations as a practitioner under 21 U.S.C. 823(f), for reason that he is not currently authorized to handle controlled substances in the State of Louisiana.

In a letter dated March 4, 1997, Dr. Katta requested an extension of time of 30 days to respond to the Order to Show Cause in order to enable him to obtain legal counsel. By order dated March 10, 1997, Administrative Law Judge Mary Ellen Bittner granted Dr. Katta an extension of time to respond until April 10, 1997. Thereafter, on April 21, 1997, Judge Bittner issued an Order Terminating Proceedings in light of Dr. Katta's failure to file a request for a hearing on the issues raised by the Order to Show Cause.

The Acting Deputy Administrator concludes that since Dr. Katta failed to file a request for a hearing within the allotted time period, he is deemed to have waived his opportunity for a hearing. After considering the relevant material from the investigative file in this matter, the Acting Deputy Administrator now enters his final order without a hearing pursuant to 21 CFR 1301.43 (d) and (e) and 1301.46.

The Acting Deputy Administrator finds that by a Consent Order dated August 24, 1995, the Louisiana State Board of Medical Examiners (Board) ordered the suspension of Dr. Katta's license to practice medicine for five years, beginning on September 1, 1995, but then stayed the suspension six months after the effective date, and placed his license on probation beginning on March 1, 1996 until September 1, 2000, subject to various conditions. One of the conditions imposed by the Board was that ''Dr. Katta may not, at any time following the execution of this agreement by the Board and for the remainder of his medical career, prescribe, dispense, or administer any legally controlled dangerous substance. * * * The Board further ordered however, that ''[t]his prohibition shall not extend to medications ordered or prescriptions written by Dr. Katta for institutional or hospital in-patients, under the permit or license of said institution or hospital.''

The Acting Deputy Administrator concludes that in light of the Board's action, Dr. Katta is not currently authorized by the State of Louisiana to independently handle controlled substances. While the Board does not prohibit Dr. Katta from handling controlled substances in a hospital setting, he may only do so by using the hospital's permit or license, and not by using a permit or license issued to him.

The DEA does not have statutory authority under the Controlled Substances Act to issue or maintain a registration if the applicant or registrant

is without state authority to handle controlled substances in the state in which he conducts his business. 21 U.S.C. 802(21), 823(f) and 824(a)(3). This prerequisite has been consistently upheld. *See* Romeo J. Perez, M.D., 62 FR 16,193 (1997); Demetris A. Green, M.D., 61 FR 60,728 (1996); Dominick A. Ricci, M.D., 58 FR 51,104 (1993).

Here, in light of the Board's Consent Order, it is clear that Dr. Katta is not authorized to handle controlled substances on his own in the State of Louisiana, and is only authorized to handle controlled substances in a hospital setting using the state and DEA registrations issued to the hospital. Therefore, Dr. Katta is not entitled to a DEA registration in that state.

Accordingly, the Acting Deputy Administrator of the Drug Enforcement Administration, pursuant to the authority vested in him by 21 U.S.C. 823 and 824 and 28 CFR 0.100(b) and 0.104, hereby orders that DEA Certificates of Registration, AK3284647 and BK2580769, previously issued to Chandra M. Katta, M.D., be, and they hereby are, revoked. The Acting Deputy Administrator further orders that any pending applications for the renewal of such registrations, be, and they hereby are, denied. This order is effective July 14, 1997.

Dated: June 5, 1997.

James S. Milford,

Acting Deputy Administrator.

[FR Doc. 97–15317 Filed 6–11–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Registration

By Notice dated February 26, 1997, and published in the **Federal Register** on March 19, 1997, (62 FR 13170), Knoll Pharmaceuticals, 30 North Jefferson Road, Whippany, New Jersey 07981, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of hydromorphone (9150), a basic class of controlled substance listed in Schedule II.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Knoll Pharmaceuticals to manufacture hydromorphone is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Acting Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above in granted.

Dated: May 23, 1997.

Terrance W. Woodworth,

Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–15318 Filed 6–11–97; 8:45 am]

BILLING CODE 4410–09–M

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

Meetings of Humanities Panel

AGENCY: National Endowment for the Humanities.

ACTION: Notice of meeting.

SUMMARY: Pursuant to the provisions of the Federal Advisory Committee Act (Public Law 92–463, as amended), notice is hereby given that the following meeting of the Humanities Panel will be held at the Old Post Office, 1100 Pennsylvania Avenue, NW., Washington, DC 20506.

FOR FURTHER INFORMATION CONTACT: Nancy E. Weiss, Advisory Committee Management Officer, National Endowment for the Humanities, Washington, DC 20506; telephone (202) 606–8322. Hearing-impaired individuals are advised that information on this matter may be obtained by contacting the Endowment's TDD terminal on (202) 606–8282.

SUPPLEMENTARY INFORMATION: The proposed meeting is for the purpose of panel review, discussion, evaluation and recommendation on applications for financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including discussion of information given in confidence to the agency by the grant applicants. Because the proposed meeting will consider information that is likely to disclose: (1) trade secrets and commercial or financial information obtained from a person and privileged or confidential; or (2) information of a personal nature the disclosure of which would constitute a clearly unwarranted invasion of personal privacy, pursuant to authority granted me by the Chairman's Delegation of Authority to Close Advisory Committee meetings, dated July 19, 1993, I have determined that this meeting will be closed to the public pursuant to subsections (c) (4), and (6) of section 552b of Title 5, United States Code.

1. *Date:* June 19, 1997.
Time: 9:00 a.m. to 5:30 p.m.
Room: 415.
Program: This meeting will review applications for Public Programs, submitted to the Office of Enterprise for projects at the May 28, 1997 deadline.

Nancy E. Weiss,

Advisory Committee, Management Officer.

[FR Doc. 97–15434 Filed 6–11–97; 8:45 am]

BILLING CODE 7536–01–M

NUCLEAR REGULATORY COMMISSION

[Docket 70–7001]

Notice of Amendment to Certificate of Compliance GDP–1 for the U.S. Enrichment Corporation, Paducah Gaseous Diffusion Plant, Paducah, KY

The Director, Office of Nuclear Material Safety and Safeguards, has made a determination that the following amendment request is not significant in accordance with 10 CFR 76.45. In making that determination the staff concluded that: (1) There is no change in the types or significant increase in the amounts of any effluents that may be released offsite; (2) there is no significant increase in individual or cumulative occupational radiation exposure; (3) there is no significant construction impact; (4) there is no significant increase in the potential for, or radiological or chemical consequences from, previously analyzed accidents; (5) the proposed changes do not result in the possibility of a new or different kind of accident; (6) there is no significant reduction in any margin of safety; and (7) the proposed changes will not result in an overall decrease in the effectiveness of the plant's safety, safeguards or security programs. The basis for this determination for the amendment request is shown below.

The NRC staff has reviewed the certificate amendment application and concluded that it provides reasonable assurance of adequate safety, safeguards, and security, and compliance with NRC requirements. Therefore, the Director, Office of Nuclear Material Safety and Safeguards, is prepared to issue an amendment to the Certificate of Compliance for the Paducah Gaseous Diffusion Plant. The staff has prepared a Compliance Evaluation Report which provides details of the staff's evaluation.

The NRC staff has determined that this amendment satisfies the criteria for a categorical exclusion in accordance with 10 CFR 51.22. Therefore, pursuant to 10 CFR 51.22(b), no environmental impact statement or environmental